What is ESMO-CoCARE
ESMO has launched an international collaborative project, the ESMO-CoCARE Registry, to quickly gather data and information from healthcare professionals about treatment approaches specifically focusing on the impact of SARS-CoV-2 on cancer patients who are suspected or confirmed to have the novel coronavirus disease (COVID19).
Pooling real-world data will make it possible to rapidly accumulate knowledge, which will allow to disseminate information and guidance for patients. Ultimately the project aims to propose approaches to mitigate the risks related to COVID-19 in cancer patients.
The survey is comprised of several parts, including patient demographics, COVID-19 and cancer diagnosis and treatment, and the evolution of both diseases.
Benefits for joining centres
- Opportunity to collaborate in a joint endeavour with colleagues from around the world;
- Contributing to a better understanding of the effects of COVID-19 on cancer patients;
- Retaining full access to own patients’ data for further analysis.
Eligibility to participate
The ESMOCoCARE Registry initiative is open to cancer centres and organisations from across Europe and around the world. To increase the rate at which information can be collected, a partnership between ESMO-CoCARE and the CCC19 Consortium has been established. For practical and organisational reasons, the two initiatives cover different geographical locations.
- Emanuela Romano, Institut Curie, Paris, France
- Luis Castelo-Branco, Algarve University Hospital, Portugal
- Olivier Michielin, Lausanne University Hospital, Switzerland
- Kevin J. Harrington, The Institute of Cancer Research, London, UK
- Jean-Yves Douillard, Lugano, Switzerland (ESMO Chief Medical Officer)
- Dirk Arnold, University Hamburg, Asklepios Tumorzentrum, AK Altona, Hamburg, Germany
- Jennifer Whisenant Gray, Vanderbilt University, Nashville, TN, USA
- Toni Choueiri, Dana-Farber Cancer Institute, Boston, MA, USA
- Solange Peters, Lausanne University Hospital, Switzerland (ESMO President)